Biotechnology Cell Therapy Clinical Trials Immunotherapies stem cells

Dana-Farber researchers report clinical trial results in treatment of leukemia and lymphoma

New results from clinical trials of immunotherapy and experimental targeted agents for patients with leukemia and lymphoma are being presented by Dana-Farber Cancer Institute researchers at the American Society of Hematology (ASH) Annual Meeting Dec. 1-4.  Here are summaries of three presentations, including one that compared outcomes of CAR T-cell therapy in patients in clinical trials with outcomes in the “real world” of clinical practice: CAR T-cell treatment provides durable
Cancer Discovery

Scientists build a new model of CAR-T cells — Ones with Powerful “Armor” that allow them to fight Solid Tumors

Engineered T-cell therapy, and in particular CAR T-cells, have shown efficacy in CD-19+ blood cancer such as lymphomas and leukemias. However, to date, T-cell therapies have found little success in solid tumors – in part due to the immunosuppressive tumor microenvironment. Checkpoint inhibitors, on the other hand, have been proven effective at empowering the immune system to fight a variety of solid tumors. The checkpoint inhibitor antibody binds to a
cancer Immunotherapies

First In-Human Clinical Trial Targeting CD4 Protein for Aggressive T-cell Leukemia and Lymphoma to be Launched

Stony Brook University, iCell Gene Therapeutics, and the University of Louisville, have received Food and Drug Administration (FDA) clearance for an Investigational New Drug (IND) for the treatment of relapsed and refractory T-cell leukemia and lymphoma. The approach is the first to use chimeric antigen receptor engineered T-cells directed against the target protein CD4 (CD4CAR). Together, Stony Brook University, the University of Louisville, and iCell Gene Therapeutics expect the first
cancer Cancer Discovery

New CAR T Case Study Shows Promise in Acute Myeloid Leukemia

Chimeric Antigen Receptor T-cell therapy, also known as CAR T therapy, was named the biggest research breakthrough of 2017 by the American Society of Clinical Oncology. The personal gene therapy utilizes a patient’s own immune cells to fight cancer. The Food and Drug Administration has approved CAR T therapy products for adults with diffuse large B-cell lymphoma and pediatric and young adults suffering from acute lymphoblastic leukemia. Now, researchers at
Biotechnology cancer Cell Therapy

FDA Approves CAR T Therapy for Large B-Cell Lymphoma Developed at University of Pennsylvania

The U.S. Food and Drug Administration (FDA) has expanded approval for a personalized cellular therapy developed at the University of Pennsylvania’s Abramson Cancer Center, this time for the treatment of adult patients with relapsed or refractory large B-Cell lymphoma after two or more lines of systemic therapy. Today’s approval includes treatment of diffuse large B-cell lymphoma (DLBCL) – the most common form of non-Hodgkin’s lymphoma – as well as high
Cancer Discovery

CAR-T cell therapy has the potential to treat brain tumors

New research shows that an immunotherapy called CAR-T cell therapy - currently only effective in treating blood cancer - has the potential to treat solid tumors, such as brain tumors The study, recently published in the Proceedings of the National Academy of Sciences, was led by Dr Misty Jenkins from the Walter and Eliza Institute of Medical Research, Australia. It explains the manner in which CAR-T cell therapy is able
Pharmaceutical Business News

Gilead to buy Kite Pharma in $11.9 billion deal

Reuters -- Gilead Sciences agreed to buy Kite Pharma in a $11.9 billion deal on Monday, as it looks to fuel growth with an emerging class of cancer immunotherapies that are expected to generate billions. Gilead will pay $180 per share in an all-cash deal, representing a 29.4 percent premium over Kite's Friday close. Kite's shares were trading up at $178.15 before the bell. Santa Monica, California-based Kite is developing
Biotechnology Clinical Trials Gene Therapy Uncategorized

CAR T-Cell Therapy for Leukemia Leads to Remissions in Clinical Trial

In an early-phase clinical trial of an experimental immunotherapy, researchers achieved durable molecular remissions in patients with chronic lymphocytic leukemia who had failed other treatments Researchers at Fred Hutchinson Cancer Research Center showed about 70 percent of patients with the most common adult leukemia had their tumors shrink or disappear following an experimental chimeric antigen receptor (CAR) T-cell immunotherapy. The researchers also found that measuring genetic traces of cancer cells
cancer Clinical Trials Immunotherapies

Experimental CAR-T Treatment Halted as Two More Patients Die During Clinical Trials

Juno Therapeutics said Wednesday it has suspended a Phase II clinical trial of a cancer drug after two patients suffered cerebral edema earlier this week, leaving one dead and the other not expected to recover. The company’s ‘Rocket’ trial for B cell acute lymphoblastic leukemia is testing a drug it calls JCAR015. These drugs work by extracting T cells from patients and then equipping them with chimeric antigen receptors, which
Cell Therapy Pharmaceutical Business News

Novartis Dissolves Its Cell Therapy Unit; 120 Positions Eliminated

Novartis AG said it will fold its specialized cell and gene therapies unit into other parts of the company, leading to about 120 job cuts months before seeking approval for a new type of cancer treatment. Cell and gene therapy development will no longer be housed in a separate division, the Basel, Switzerland-based company said Wednesday. The change won’t affect a plan to apply for U.S. approval early next year
Biotechnology Pharmaceutical Business News

Cancer Trial for Leukemia Halted after Death of Two Patients

The U.S. Food and Drug Administration placed a hold on a Juno Therapeutics clinical trial of a treatment for a form of leukemia following the death of two trial patients last week. The Company said in a press announcement that both deaths occurred last week after the patients, who had relapsed or refractory B cell acute lymphoblastic leukemia, took the drug fludarabine before receiving the chimeric antigen receptor (CAR) T cells
Biotechnology Pharmaceutical Business News Pharmaceuticals

Q&A with Denis Corin, Q Bio Med Inc – Getting Past the “Pharma Bro” – Smaller Biotech Continue to Strive for Well-Being of Patients

There has been a vast amount of mixed feelings surrounding the biotech/drug company development of drugs and the final price consumers/patients are paying. Especially when one biotech CEO, Martin Shkreli (aka ‘Pharma Bro”) decided to massively increase of a very cheap drug vital to patients with HIV from $13.50 to $750. The actions of one CEO has cast an unjust dark shadow on peers in the industry. According to Denis Corin,